LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
24th FDA Approval for Butchertown Clinical Trials
August 4, 2025
LENZ Therapeutics, Inc. announced the US Food and Drug Administration (“FDA”) approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults.
“In clinical trials, the mechanism of action of this eye drop was highly effective in treating adults with presbyopia for up to ten hours. This new eye drop uses aceclidine as the active ingredient, marking the first time the US FDA has approved this chemical for the treatment of presbyopia”, said Renee S. McEntire, OD, who worked as Sub Investigator on the new drug at Butchertown Clinical Trials with John C. Meyer, MD, as Principal Investigator.
Vizz is a once-daily eye drop that works within 30 minutes and lasts for up to ten hours. It is available by prescription through your eye doctor.
“This marks our 24th FDA approval and our third FDA approval of 2025. Along with our sponsoring scientific research partners, including those in the pharmaceutical and biotechnology space, we have several new treatments pending before the FDA so there are more announcements pending, as we are pleased to continue to offer new treatment options and to help improve human health through our Louisville, KY-based clinical trials site, Butchertown Clinical Trials,” said Mark Prussian, CEO and co-founder.
Butchertown Clinical Trials is an affiliate of The Eye Care Institute.
# # #
